Translocating Lactobacillus torments tumors via tryptophan catabolism

Márcia S Pereira; Martin A Kriegel

doi:10.1016/j.cell.2023.03.022

Translocating Lactobacillus torments tumors via tryptophan catabolism

Cell. 2023 Apr 27;186(9):1821-1823. doi: 10.1016/j.cell.2023.03.022.

Authors

Márcia S Pereira¹, Martin A Kriegel²

Affiliations

¹ Department of Translational Rheumatology and Immunology, Institute of Musculoskeletal Medicine, University of Münster, 48149 Münster, Germany.
² Department of Translational Rheumatology and Immunology, Institute of Musculoskeletal Medicine, University of Münster, 48149 Münster, Germany; Section of Rheumatology and Clinical Immunology, Department of Internal Medicine, University Hospital Münster, 48149 Münster, Germany; Cells in Motion Interfaculty Centre, University of Münster, 48149 Münster, Germany; Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06511, USA. Electronic address: martin.kriegel@ukmuenster.de.

PMID: 37116468
DOI: 10.1016/j.cell.2023.03.022

Abstract

Variability in the efficacy of immune checkpoint inhibitors in cancer patients is associated with the human gut microbiota. However, detailed mechanisms are unclear. In this issue of Cell, Bender et al. uncovered that a probiotic Lactobacillus strain translocates into murine tumors to enhance immunotherapy via the tryptophan metabolite indole-3-aldehyde (I3A).

Publication types

Comment

MeSH terms

Animals
Gastrointestinal Microbiome*
Humans
Immunotherapy
Lactobacillus*
Mice
Neoplasms* / immunology
Tryptophan* / metabolism

Substances

Tryptophan